Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy
Abstract
:1. Introduction
2. NPC Populations of the Liver Contribute to its Tolerogenic Activity
2.1. Immunological Role of LSECs
2.2. Immune-Relevant Properties of LSEC
2.2.1. Phenotype
2.2.2. Endocytic Capacity
2.2.3. Immune Functions
2.2.4. Targeting of LSEC with Nanocarriers
2.3. Liver Macrophages Maintain Tolerance under Homeostatic Conditions
2.3.1. KCs Are the Main Macrophage Population under Homeostatic Conditions
2.3.2. KCs Promote Tolerance by Default but Exert Pro-Inflammatory Activity in Case of Liver Inflammation
2.3.3. Targeting Hepatic Macrophage Populations with Nanocarriers for Immunotherapy
Passive Targeting
Active Targeting
Reprogramming of Liver Macrophages
2.4. Immunorelevant Functions of HSC
2.4.1. Immune Functions
2.4.2. HSC as a Target for Nanocarriers for Immunotherapy
3. HCC—Risk Factors and Current Treatment
3.1. Risk Factors for HCC
3.2. Current Treatment Options for HCC
3.3. Macrophages Are Key Players in HCC Progression
3.4. Targeting of TAMs with NPs for Tumor Therapy
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
Abbreviations
APC | antigen presenting cell |
APF | 4-aminophenyl-β-l-fucopyranoside |
APM | 4-aminophenyl-α-d-mannopyranoside |
ASK-1 | apoptosis signal-regulating kinase 1 |
CAF | cancer-associated fibroblasts |
CLR | C-type lectin receptor |
CCL | chemokine (C-C motif) ligand |
CLR | C-type lectin receptor |
CR | complement receptor |
CSF-1 | colony stimulating factor 1 |
CTL | cytotoxic T lymphocyte |
CXCL | chemokine (C-X-C motif) ligand |
DC | dendritic cell |
DC-SIGNR | DC-SIGN-related protein |
FcR | Fc receptor |
HCC | hepatocellular carcinoma |
HSC | hepatic stellate cell |
ICAM | intercellular adhesion molecule |
IFN | interferon |
IL | interleukin |
IRF | interferon regulatory factor |
KC | Kupffer cell |
L-SIGN | liver/lymph node-specific intercellular adhesion molecule [ICAM]-3 grabbing non-integrin |
LSEC | liver sinusoidal endothelial cells |
LYVE-1 | lymphatic vessel endothelial receptor 1 |
M6P | mannose-6-phosphat |
ManNP | mannose-functionalized nanohydrogel particles |
MARCO | macrophage receptor with collagenous structure |
MDSC | myeloid-derived suppressor cell |
MHC | major histocompatibility complex |
MMP | matrix metalloproteinase |
MoMF | monocyte-derived macrophages |
NAFLD | non-alcoholic fatty liver disease |
NF-κB | nuclear factor kappa B |
NKT | natural killer T cell |
NOD | nucleotide binding oligomerization domain containing |
NPC | non-parenchymal cell |
NP | nanoparticle |
PDGF | platelet-derived growth factor |
PD-L1 | programmed death-ligand 1 |
PPAR | peroxisome proliferator activated receptor |
RBP | retinol binding protein |
PRR | pathogen-associated molecular pattern |
RIG | retinoic acid-inducible gene |
RLR | RIG-like receptor |
SCAR | scavenger receptor |
siRNA | small interfering RNA |
STAT | signal transducer and activator of transcription |
TAM | tumor-associated macrophage |
TEM | tumor microenvironment |
TIME | tumor immune microenvironment |
TGF | tumor growth factor |
Th | T helper cell |
TLR | Toll-like receptor |
Treg | regulatory T cell |
VAP | vascular adhesion protein |
VCAM | vascular cell adhesion protein |
VEGFR | vascular endothelial growth factor |
VWF | von-Willebrand-Factor |
References
- Lungu, I.I.; Grumezescu, A.M.; Volceanov, A.; Andronescu, E. Nanobiomaterials Used in Cancer Therapy: An Up-To-Date Overview. Molecules 2019, 24, 3547. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kranz, L.M.; Diken, M.; Haas, H.; Kreiter, S.; Loquai, C.; Reuter, K.C.; Meng, M.; Fritz, D.; Vascotto, F.; Hefesha, H.; et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016, 534, 396–401. [Google Scholar] [CrossRef] [PubMed]
- Baetke, S.C.; Lammers, T.; Kiessling, F. Applications of nanoparticles for diagnosis and therapy of cancer. Br. J. Radiol. 2015, 88, 20150207. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.R.; Nam, K.; Lee, B.J.; Lee, S.W.; Baek, S.M.; Bang, J.S.; Choi, S.K.; Park, S.J.; Kim, T.H.; Jeong, K.S.; et al. Hepatic Cellular Distribution of Silica Nanoparticles by Surface Energy Modification. Int. J. Mol. Sci. 2019, 20, 3812. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vijayan, V.; Mohapatra, A.; Uthaman, S.; Park, I.K. Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials. Pharmaceutics 2019, 11, 534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, S.Y.; Liu, Y.; Xu, C.F.; Shen, S.; Sun, R.; Du, X.J.; Xia, J.X.; Zhu, Y.H.; Wang, J. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. J. Control. Release 2016, 231, 17–28. [Google Scholar] [CrossRef]
- Schmetterer, K.G.; Pickl, W.F. The IL-10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory T-cells. Eur. J. Immunol. 2017, 47, 1256–1265. [Google Scholar] [CrossRef] [Green Version]
- Paulis, L.E.; Mandal, S.; Kreutz, M.; Figdor, C.G. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 2013, 25, 389–395. [Google Scholar] [CrossRef]
- Liu, J.; Wang, J.; Zhu, Q.; Yu, C.; Yin, J.; Zheng, L.; Li, A. Mannosylated PEGylated-Polyethyleneimine as Efficient CpG Oligodeoxynucleotide Carriers for Efficient Dendritic Cell Targeting Delivery and Activation. J. Biomed. Nanotechnol. 2019, 15, 1454–1467. [Google Scholar] [CrossRef]
- Souto, E.B.; Ribeiro, A.F.; Ferreira, M.I.; Teixeira, M.C.; Shimojo, A.A.M.; Soriano, J.L.; Naveros, B.C.; Durazzo, A.; Lucarini, M.; Souto, S.B.; et al. New Nanotechnologies for the Treatment and Repair of Skin Burns Infections. Int. J. Mol. Sci. 2020, 21, 393. [Google Scholar] [CrossRef] [Green Version]
- Meng, H.; Leong, W.; Leong, K.W.; Chen, C.; Zhao, Y. Walking the line: The fate of nanomaterials at biological barriers. Biomaterials 2018, 174, 41–53. [Google Scholar] [CrossRef] [PubMed]
- Surendran, S.P.; Thomas, R.G.; Moon, M.J.; Jeong, Y.Y. Nanoparticles for the treatment of liver fibrosis. Int. J. Nanomed. 2017, 12, 6997–7006. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yong, S.B.; Chung, J.Y.; Song, Y.; Kim, J.; Ra, S.; Kim, Y.H. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Biomaterials 2019, 219, 119401. [Google Scholar] [CrossRef] [PubMed]
- Zheng, M.; Tian, Z. Liver-Mediated Adaptive Immune Tolerance. Front. Immunol. 2019, 10, 2525. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dou, L.; Ono, Y.; Chen, Y.F.; Thomson, A.W.; Chen, X.P. Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease. Semin. Liver Dis. 2018, 38, 170–180. [Google Scholar] [CrossRef] [PubMed]
- Samuelsson, E.; Shen, H.; Blanco, E.; Ferrari, M.; Wolfram, J. Contribution of Kupffer cells to liposome accumulation in the liver. Colloids Surf. B Biointerfaces 2017, 158, 356–362. [Google Scholar] [CrossRef] [PubMed]
- Park, J.K.; Utsumi, T.; Seo, Y.E.; Deng, Y.; Satoh, A.; Saltzman, W.M.; Iwakiri, Y. Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomed. Nanotechnol. Biol. Med. 2016, 12, 1365–1374. [Google Scholar] [CrossRef] [Green Version]
- Poisson, J.; Lemoinne, S.; Boulanger, C.; Durand, F.; Moreau, R.; Valla, D.; Rautou, P.E. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J. Hepatol. 2017, 66, 212–227. [Google Scholar] [CrossRef] [Green Version]
- Karrar, A.; Broome, U.; Uzunel, M.; Qureshi, A.R.; Sumitran-Holgersson, S. Human liver sinusoidal endothelial cells induce apoptosis in activated T cells: A role in tolerance induction. Gut 2007, 56, 243–252. [Google Scholar] [CrossRef] [Green Version]
- Sorensen, K.K.; Simon-Santamaria, J.; McCuskey, R.S.; Smedsrod, B. Liver Sinusoidal Endothelial Cells. Compr. Physiol. 2015, 5, 1751–1774. [Google Scholar] [CrossRef] [Green Version]
- Ganesan, L.P.; Kim, J.; Wu, Y.; Mohanty, S.; Phillips, G.S.; Birmingham, D.J.; Robinson, J.M.; Anderson, C.L. FcgammaRIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol. 2012, 189, 4981–4988. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elvevold, K.; Simon-Santamaria, J.; Hasvold, H.; McCourt, P.; Smedsrod, B.; Sorensen, K.K. Liver sinusoidal endothelial cells depend on mannose receptor-mediated recruitment of lysosomal enzymes for normal degradation capacity. Hepatology 2008, 48, 2007–2015. [Google Scholar] [CrossRef] [PubMed]
- DeLeve, L.D.; Maretti-Mira, A.C. Liver Sinusoidal Endothelial Cell: An Update. Semin. Liver Dis. 2017, 37, 377–387. [Google Scholar] [CrossRef] [PubMed]
- Xie, G.; Wang, L.; Wang, X.; Wang, L.; DeLeve, L.D. Isolation of periportal, midlobular, and centrilobular rat liver sinusoidal endothelial cells enables study of zonated drug toxicity. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299, G1204–G1210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lertkiatmongkol, P.; Liao, D.; Mei, H.; Hu, Y.; Newman, P.J. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr. Opin. Hematol. 2016, 23, 253–259. [Google Scholar] [CrossRef] [Green Version]
- Dingle, A.M.; Yap, K.K.; Gerrand, Y.W.; Taylor, C.J.; Keramidaris, E.; Lokmic, Z.; Kong, A.M.; Peters, H.L.; Morrison, W.A.; Mitchell, G.M. Characterization of isolated liver sinusoidal endothelial cells for liver bioengineering. Angiogenesis 2018, 21, 581–597. [Google Scholar] [CrossRef]
- Simon-Santamaria, J.; Malovic, I.; Warren, A.; Oteiza, A.; Le Couteur, D.; Smedsrod, B.; McCourt, P.; Sorensen, K.K. Age-related changes in scavenger receptor-mediated endocytosis in rat liver sinusoidal endothelial cells. J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65, 951–960. [Google Scholar] [CrossRef] [Green Version]
- Meyer, J.; Gonelle-Gispert, C.; Morel, P.; Buhler, L. Methods for Isolation and Purification of Murine Liver Sinusoidal Endothelial Cells: A Systematic Review. PLoS ONE 2016, 11, e0151945. [Google Scholar] [CrossRef] [Green Version]
- Busold, S.; Nagy, N.A.; Tas, S.W.; van Ree, R.; de Jong, E.C.; Geijtenbeek, T.B.H. Various Tastes of Sugar: The Potential of Glycosylation in Targeting and Modulating Human Immunity via C-Type Lectin Receptors. Front. Immunol. 2020, 11, 134. [Google Scholar] [CrossRef] [Green Version]
- Mnich, M.E.; van Dalen, R.; van Sorge, N.M. C-Type Lectin Receptors in Host Defense Against Bacterial Pathogens. Front. Cell Infect. Microbiol. 2020, 10, 309. [Google Scholar] [CrossRef]
- Drouin, M.; Saenz, J.; Chiffoleau, E. C-Type Lectin-Like Receptors: Head or Tail in Cell Death Immunity. Front. Immunol. 2020, 11, 251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nonaka, M.; Ma, B.Y.; Murai, R.; Nakamura, N.; Baba, M.; Kawasaki, N.; Hodohara, K.; Asano, S.; Kawasaki, T. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells. J. Immunol. 2008, 180, 3347–3356. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Del Fresno, C.; Iborra, S.; Saz-Leal, P.; Martínez-López, M.; Sancho, D. Flexible Signaling of Myeloid C-Type Lectin Receptors in Immunity and Inflammation. Front. Immunol. 2018, 9, 804. [Google Scholar] [CrossRef] [PubMed]
- Pustylnikov, S.; Sagar, D.; Jain, P.; Khan, Z.K. Targeting the C-type lectins-mediated host-pathogen interactions with dextran. J. Pharm. Pharm. Sci. 2014, 17, 371–392. [Google Scholar] [CrossRef] [Green Version]
- Zhang, F.; Ren, S.; Zuo, Y. DC-SIGN, DC-SIGNR and LSECtin: C-type lectins for infection. Int. Rev. Immunol. 2014, 33, 54–66. [Google Scholar] [CrossRef]
- Van den Berg, L.M.; Gringhuis, S.I.; Geijtenbeek, T.B. An evolutionary perspective on C-type lectins in infection and immunity. Ann. N. Y. Acad. Sci. 2012, 1253, 149–158. [Google Scholar] [CrossRef]
- Yang, Z.; Li, Q.; Wang, X.; Jiang, X.; Zhao, D.; Lin, X.; He, F.; Tang, L. C-type lectin receptor LSECtin-mediated apoptotic cell clearance by macrophages directs intestinal repair in experimental colitis. Proc. Natl. Acad. Sci. USA 2018, 115, 11054–11059. [Google Scholar] [CrossRef] [Green Version]
- Domínguez-Soto, A.; Aragoneses-Fenoll, L.; Gómez-Aguado, F.; Corcuera, M.T.; Clária, J.; García-Monzón, C.; Bustos, M.; Corbí, A.L. The pathogen receptor liver and lymph node sinusoidal endotelial cell C-type lectin is expressed in human Kupffer cells and regulated by PU.1. Hepatology 2009, 49, 287–296. [Google Scholar] [CrossRef]
- Malovic, I.; Sorensen, K.K.; Elvevold, K.H.; Nedredal, G.I.; Paulsen, S.; Erofeev, A.V.; Smedsrod, B.H.; McCourt, P.A. The mannose receptor on murine liver sinusoidal endothelial cells is the main denatured collagen clearance receptor. Hepatology 2007, 45, 1454–1461. [Google Scholar] [CrossRef]
- Cormier, E.G.; Durso, R.J.; Tsamis, F.; Boussemart, L.; Manix, C.; Olson, W.C.; Gardner, J.P.; Dragic, T. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. USA 2004, 101, 14067–14072. [Google Scholar] [CrossRef] [Green Version]
- Tanigaki, K.; Sundgren, N.; Khera, A.; Vongpatanasin, W.; Mineo, C.; Shaul, P.W. Fcgamma receptors and ligands and cardiovascular disease. Circ. Res. 2015, 116, 368–384. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, J.; Meng, Z.; Jiang, M.; Zhang, E.; Trippler, M.; Broering, R.; Bucchi, A.; Krux, F.; Dittmer, U.; Yang, D.; et al. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 2010, 129, 363–374. [Google Scholar] [CrossRef] [PubMed]
- Huang, S.; Wu, J.; Gao, X.; Zou, S.; Chen, L.; Yang, X.; Sun, C.; Du, Y.; Zhu, B.; Li, J.; et al. LSECs express functional NOD1 receptors: A role for NOD1 in LSEC maturation-induced T cell immunity in vitro. Mol. Immunol. 2018, 101, 167–175. [Google Scholar] [CrossRef] [PubMed]
- Kruse, N.; Neumann, K.; Schrage, A.; Derkow, K.; Schott, E.; Erben, U.; Kuhl, A.; Loddenkemper, C.; Zeitz, M.; Hamann, A.; et al. Priming of CD4+ T cells by liver sinusoidal endothelial cells induces CD25low forkhead box protein 3- regulatory T cells suppressing autoimmune hepatitis. Hepatology 2009, 50, 1904–1913. [Google Scholar] [CrossRef] [PubMed]
- Rubinstein, D.; Roska, A.K.; Lipsky, P.E. Liver sinusoidal lining cells express class II major histocompatibility antigens but are poor stimulators of fresh allogeneic T lymphocytes. J. Immunol. 1986, 137, 1803–1810. [Google Scholar]
- Damle, N.K.; Aruffo, A. Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+T lymphocytes. Proc. Natl. Acad. Sci. USA 1991, 88, 6403–6407. [Google Scholar] [CrossRef] [Green Version]
- Lalor, P.F.; Edwards, S.; McNab, G.; Salmi, M.; Jalkanen, S.; Adams, D.H. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J. Immunol. 2002, 169, 983–992. [Google Scholar] [CrossRef] [Green Version]
- Slawek, A.; Maj, T.; Chelmonska-Soyta, A. CD40, CD80, and CD86 costimulatory molecules are differentially expressed on murine splenic antigen-presenting cells during the pre-implantation period of pregnancy, and they modulate regulatory T-cell abundance, peripheral cytokine response, and pregnancy outcome. Am. J. Reprod. Immunol. 2013, 70, 116–126. [Google Scholar] [CrossRef]
- Knolle, P.A.; Wohlleber, D. Immunological functions of liver sinusoidal endothelial cells. Cell. Mol. Immunol. 2016, 13, 347–353. [Google Scholar] [CrossRef] [Green Version]
- Berg, M.; Wingender, G.; Djandji, D.; Hegenbarth, S.; Momburg, F.; Hammerling, G.; Limmer, A.; Knolle, P. Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance. Eur. J. Immunol. 2006, 36, 2960–2970. [Google Scholar] [CrossRef]
- Blander, J.M. Regulation of the Cell Biology of Antigen Cross-Presentation. Annu. Rev. Immunol. 2018, 36, 717–753. [Google Scholar] [CrossRef]
- Diehl, L.; Schurich, A.; Grochtmann, R.; Hegenbarth, S.; Chen, L.; Knolle, P.A. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. Hepatology 2008, 47, 296–305. [Google Scholar] [CrossRef] [PubMed]
- Knolle, P.A.; Germann, T.; Treichel, U.; Uhrig, A.; Schmitt, E.; Hegenbarth, S.; Lohse, A.W.; Gerken, G. Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J. Immunol. 1999, 162, 1401–1407. [Google Scholar] [PubMed]
- Carambia, A.; Frenzel, C.; Bruns, O.T.; Schwinge, D.; Reimer, R.; Hohenberg, H.; Huber, S.; Tiegs, G.; Schramm, C.; Lohse, A.W.; et al. Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells. J. Hepatol. 2013, 58, 112–118. [Google Scholar] [CrossRef] [PubMed]
- Neumann, K.; Rudolph, C.; Neumann, C.; Janke, M.; Amsen, D.; Scheffold, A. Liver sinusoidal endothelial cells induce immunosuppressive IL-10-producing Th1 cells via the Notch pathway. Eur. J. Immunol. 2015, 45, 2008–2016. [Google Scholar] [CrossRef]
- Liu, J.; Jiang, M.; Ma, Z.; Dietze, K.K.; Zelinskyy, G.; Yang, D.; Dittmer, U.; Schlaak, J.F.; Roggendorf, M.; Lu, M. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro. J. Immunol. 2013, 191, 6178–6190. [Google Scholar] [CrossRef] [Green Version]
- Liu, Q.; Wang, X.; Liu, X.; Kumar, S.; Gochman, G.; Ji, Y.; Liao, Y.P.; Chang, C.H.; Situ, W.; Lu, J.; et al. Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model. ACS Nano 2019, 13, 4778–4794. [Google Scholar] [CrossRef]
- Arosio, D.; Chiodo, F.; Reina, J.J.; Marelli, M.; Penades, S.; van Kooyk, Y.; Garcia-Vallejo, J.J.; Bernardi, A. Effective targeting of DC-SIGN by alpha-fucosylamide functionalized gold nanoparticles. Bioconjug. Chem. 2014, 25, 2244–2251. [Google Scholar] [CrossRef] [Green Version]
- Toth, C.A.; Thomas, P. Liver endocytosis and Kupffer cells. Hepatology 1992, 16, 255–266. [Google Scholar] [CrossRef]
- Ishikawa, T.; Yokoyama, H.; Matsuura, T.; Fujiwara, Y. Fc gamma RIIb expression levels in human liver sinusoidal endothelial cells during progression of non-alcoholic fatty liver disease. PLoS ONE 2019, 14, e0211543. [Google Scholar] [CrossRef]
- Jenne, C.N.; Kubes, P. Immune surveillance by the liver. Nat. Immunol. 2013, 14, 996–1006. [Google Scholar] [CrossRef]
- Bonnardel, J.; T’Jonck, W.; Gaublomme, D.; Browaeys, R.; Scott, C.L.; Martens, L.; Vanneste, B.; De Prijck, S.; Nedospasov, S.A.; Kremer, A.; et al. Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the Kupffer Cell Identity on Monocytes Colonizing the Liver Macrophage Niche. Immunity 2019, 51, 638–654.e639. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bilzer, M.; Roggel, F.; Gerbes, A.L. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006, 26, 1175–1186. [Google Scholar] [CrossRef] [PubMed]
- MacParland, S.A.; Liu, J.C.; Ma, X.Z.; Innes, B.T.; Bartczak, A.M.; Gage, B.K.; Manuel, J.; Khuu, N.; Echeverri, J.; Linares, I.; et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat. Commun. 2018, 9, 4383. [Google Scholar] [CrossRef] [Green Version]
- Guillot, A.; Tacke, F. Liver Macrophages: Old Dogmas and New Insights. Hepatol. Commun. 2019, 3, 730–743. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boltjes, A.; Movita, D.; Boonstra, A.; Woltman, A.M. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J. Hepatol. 2014, 61, 660–671. [Google Scholar] [CrossRef] [Green Version]
- Vollmar, B.; Menger, M.D. The hepatic microcirculation: Mechanistic contributions and therapeutic targets in liver injury and repair. Physiol. Rev. 2009, 89, 1269–1339. [Google Scholar] [CrossRef]
- Movita, D.; Kreefft, K.; Biesta, P.; van Oudenaren, A.; Leenen, P.J.; Janssen, H.L.; Boonstra, A. Kupffer cells express a unique combination of phenotypic and functional characteristics compared with splenic and peritoneal macrophages. J. Leukoc. Biol. 2012, 92, 723–733. [Google Scholar] [CrossRef]
- Van der Heide, D.; Weiskirchen, R.; Bansal, R. Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases. Front. Immunol. 2019, 10, 2852. [Google Scholar] [CrossRef] [Green Version]
- Chen, G.; Ni, Y.; Nagata, N.; Xu, L.; Zhuge, F.; Nagashimada, M.; Kaneko, S.; Ota, T. Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. Lab. Investig. 2019, 99, 1335–1348. [Google Scholar] [CrossRef]
- Huang, H.; Zhang, X.; Zhang, C.; Chen, H.; Ling, Q.; Zheng, S. The time-dependent shift in the hepatic graft and recipient macrophage pool following liver transplantation. Cell. Mol. Immunol. 2020, 17, 412–414. [Google Scholar] [CrossRef] [PubMed]
- Su, G.L.; Klein, R.D.; Aminlari, A.; Zhang, H.Y.; Steinstraesser, L.; Alarcon, W.H.; Remick, D.G.; Wang, S.C. Kupffer cell activation by lipopolysaccharide in rats: Role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 2000, 31, 932–936. [Google Scholar] [CrossRef] [PubMed]
- Hinglais, N.; Kazatchkine, M.D.; Mandet, C.; Appay, M.D.; Bariety, J. Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study. Lab. Investig. 1989, 61, 509–514. [Google Scholar] [PubMed]
- Hughes, D.A.; Fraser, I.P.; Gordon, S. Murine macrophage scavenger receptor: In vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. Eur. J. Immunol. 1995, 25, 466–473. [Google Scholar] [CrossRef]
- Dey, A.; Allen, J.; Hankey-Giblin, P.A. Ontogeny and polarization of macrophages in inflammation: Blood monocytes versus tissue macrophages. Front. Immunol. 2014, 5, 683. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karimi, M.H.; Geramizadeh, B.; Malek-Hosseini, S.A. Tolerance Induction in Liver. Int. J. Organ Transpl. Med. 2015, 6, 45–54. [Google Scholar]
- Heymann, F.; Peusquens, J.; Ludwig-Portugall, I.; Kohlhepp, M.; Ergen, C.; Niemietz, P.; Martin, C.; van Rooijen, N.; Ochando, J.C.; Randolph, G.J.; et al. Liver Inflammation Abrogates Immunological Tolerance Induced by Kupffer Cells. Hepatology 2015, 62, 279–291. [Google Scholar] [CrossRef]
- Tacke, F. Targeting hepatic macrophages to treat liver diseases. J. Hepatol. 2017, 66, 1300–1312. [Google Scholar] [CrossRef]
- Abdullah, Z.; Knolle, P.A. Liver macrophages in healthy and diseased liver. Pflug. Arch. Eur. J. Physiol. 2017, 469, 553–560. [Google Scholar] [CrossRef]
- Knolle, P.; Schlaak, J.; Uhrig, A.; Kempf, P.; Gerken, G.; Btischenfelde, M. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Hepatol. 1995, 22, 226–229. [Google Scholar] [CrossRef]
- Doherty, D.G. Immunity, tolerance and autoimmunity in the liver: A comprehensive review. J. Autoimmun. 2016, 66, 60–75. [Google Scholar] [CrossRef]
- Doherty, D.G. Antigen-specific immune tolerance in the liver. Nat. Biomed. Eng. 2019, 3, 763–765. [Google Scholar] [CrossRef] [PubMed]
- Jager, J.; Aparicio-Vergara, M.; Aouadi, M. Liver innate immune cells and insulin resistance: The multiple facets of Kupffer cells. J. Intern. Med. 2016, 280, 209–220. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scott, C.L.; Zheng, F.; De Baetselier, P.; Martens, L.; Saeys, Y.; De Prijck, S.; Lippens, S.; Abels, C.; Schoonooghe, S.; Raes, G.; et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat. Commun. 2016, 7, 10321. [Google Scholar] [CrossRef] [PubMed]
- Colino, C.I.; Lanao, J.M.; Gutierrez-Millan, C. Targeting of Hepatic Macrophages by Therapeutic Nanoparticles. Front. Immunol. 2020, 11, 218. [Google Scholar] [CrossRef] [Green Version]
- MacParland, S.A.; Tsoi, K.M.; Ouyang, B.; Ma, X.Z.; Manuel, J.; Fawaz, A.; Ostrowski, M.A.; Alman, B.A.; Zilman, A.; Chan, W.C.W.; et al. Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood. ACS Nano 2017, 11, 2428–2443. [Google Scholar] [CrossRef]
- Gan, Z.; Lokugamage, M.P.; Hatit, M.Z.C.; Loughrey, D.; Paunovska, K.; Sato, M.; Cristian, A.; Dahlman, J.E. Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands. Bioeng. Transl. Med. 2020. [Google Scholar] [CrossRef] [Green Version]
- Saito, E.; Kuo, R.; Kramer, K.R.; Gohel, N.; Giles, D.A.; Moore, B.B.; Miller, S.D.; Shea, L.D. Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease. Biomaterials 2019, 222, 119432. [Google Scholar] [CrossRef]
- Hunter, Z.; McCarthy, D.P.; Yap, W.T.; Harp, C.T.; Getts, D.R.; Shea, L.D.; Miller, S.D. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 2014, 8, 2148–2160. [Google Scholar] [CrossRef]
- Ergen, C.; Heymann, F.; Al Rawashdeh, W.; Gremse, F.; Bartneck, M.; Panzer, U.; Pola, R.; Pechar, M.; Storm, G.; Mohr, N.; et al. Targeting distinct myeloid cell populations in vivo using polymers, liposomes and microbubbles. Biomaterials 2017, 114, 106–120. [Google Scholar] [CrossRef]
- Melgert, B.N.; Olinga, P.; Van Der Laan, J.M.; Weert, B.; Cho, J.; Schuppan, D.; Groothuis, G.M.; Meijer, D.K.; Poelstra, K. Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats. Hepatology 2001, 34, 719–728. [Google Scholar] [CrossRef] [PubMed]
- Lai, C.; Li, C.; Luo, X.; Liu, M.; Liu, X.; Hu, L.; Kang, L.; Qiu, Q.; Deng, Y.; Song, Y. Use of Dual-Ligand Modification in Kupffer Cell-Targeted Liposomes to Examine the Contribution of Kupffer Cells to Accelerated Blood Clearance Phenomenon. Mol. Pharm. 2018, 15, 2548–2558. [Google Scholar] [CrossRef] [PubMed]
- Lai, C.; Li, C.; Liu, M.; Qiu, Q.; Luo, X.; Liu, X.; Hu, L.; Deng, Y.; Song, Y. Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes. Asian J. Pharm. Sci. 2019, 14, 455–464. [Google Scholar] [CrossRef] [PubMed]
- Cieslewicz, M.; Tang, J.; Yu, J.L.; Cao, H.; Zaèaljeèski, M.; Motoyama, K.; Lieber, A.; Raines, E.W.; Pun, S.H. Targeted delièery of proapoptotic peptides to tumor-associated macrophages improèes surèièal. Proc. Natl. Acad. Sci. USA 2013, 110, 15919–15924. [Google Scholar] [CrossRef] [Green Version]
- Qian, Y.; Qiao, S.; Dai, Y.; Xu, G.; Dai, B.; Lu, L.; Yu, X.; Luo, Q.; Zhang, Z. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. ACS Nano 2017, 11, 9536–9549. [Google Scholar] [CrossRef]
- Kakoschky, B.; Pleli, T.; Schmithals, C.; Zeuzem, S.; Brüne, B.; Vogl, T.J.; Korf, H.W.; Weigert, A.; Piiper, A. Selective targeting of tumor associated macrophages in different tumor models. PLoS ONE 2018, 13, e0193015. [Google Scholar] [CrossRef]
- Ju, C.; Tacke, F. Hepatic macrophages in homeostasis and liver diseases: From pathogenesis to novel therapeutic strategies. Cell. Mol. Immunol. 2016, 13, 316–327. [Google Scholar] [CrossRef] [Green Version]
- Liu, T.; Li, L.; Fu, C.; Liu, H.; Chen, D.; Tang, F. Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles. Biomaterials 2012, 33, 2399–2407. [Google Scholar] [CrossRef]
- Bartneck, M.; Ritz, T.; Keul, H.A.; Wambach, M.; Gbureck, U.; Ehling, J.; Lammers, T.; Heymann, F.; Gassler, N.; Lu, T.; et al. Peptide-Functionalized Gold Nanorods Increase Liver Injury in Hepatitis. ACS Nano 2012, 6, 8767–8777. [Google Scholar] [CrossRef]
- Yao, Q.; Liu, J.; Zhang, Z.; Li, F.; Zhang, C.; Lai, B.; Xiao, L.; Wang, N. Peroxisome proliferator-activated receptor γ (PPARγ) induces the gene expression of integrin α(V)β(5) to promote macrophage M2 polarization. J. Biol. Chem. 2018, 293, 16572–16582. [Google Scholar] [CrossRef] [Green Version]
- Luo, W.; Xu, Q.; Wang, Q.; Wu, H.; Hua, J. Effect of modulation of PPAR- γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci. Rep. 2017, 7, 44612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wake, K. “Sternzellen” in the liver: Perisinusoidal cells with special reference to storage of vitamin A. Am. J. Anat. 1971, 132, 429–461. [Google Scholar] [CrossRef]
- Wells, R.G. Cellular Sources of Extracellular Matrix in Hepatic Fibrosis. Clin. Liver Dis. 2008, 12, 759–768. [Google Scholar] [CrossRef] [Green Version]
- Devhare, P.B.; Sasaki, R.; Shrivastava, S.; Di Bisceglie, A.M.; Ray, R.; Ray, B. Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells. J. Virol. 2017, 91. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Puche, J.E.; Saiman, Y.; Friedman, S.L. Hepatic Stellate Cells and Liver Fibrosis. Arch. Patol. Lab. Med. 2013, 3, 1473–1492. [Google Scholar] [CrossRef]
- Gandhi, C.R. Hepatic stellate cell activation and pro-fibrogenic signals. J. Hepatol. 2017, 67, 1104–1105. [Google Scholar] [CrossRef] [Green Version]
- Mikula, M.; Proell, V.; Fischer, A.N.M.; Mikulits, W. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-β dependent fashion. J. Cell. Physiol. 2006, 209, 560–567. [Google Scholar] [CrossRef] [Green Version]
- Gandhi, C.R. Chapter 14—Stellate Cells in Hepatic Immunological Tolerance. In Stellate Cells in Health and Disease; Academic Press: Cambridge, MA, USA, 2015; pp. 227–250. [Google Scholar] [CrossRef]
- Wang, B.; Trippler, M.; Pei, R.; Lu, M.; Broering, R.; Gerken, G.; Schlaak, J.F. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. J. Hepatol. 2009, 51, 1037–1045. [Google Scholar] [CrossRef] [PubMed]
- Watanabe, A.; Hashmi, A.; Gomes, D.A.; Town, T.; Badou, A.; Flavell, R.A.; Mehal, W.Z. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007, 46, 1509–1518. [Google Scholar] [CrossRef] [PubMed]
- Bigorgne, A.E.; John, B.; Ebrahimkhani, M.R.; Shimizu-Albergine, M.; Campbell, J.S.; Crispe, I.N. TLR4-dependent secretion by hepatic stellate cells of the neutrophil-chemoattractant CXCL1 mediates liver response to gut microbiota. PLoS ONE 2016, 11, e0151063. [Google Scholar] [CrossRef] [PubMed]
- Weiskirchen, R.; Tacke, F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobil Surg. Nutr. 2014, 3, 344–363. [Google Scholar] [CrossRef]
- Yu, M.C.; Chen, C.H.; Liang, X.; Wang, L.; Gandhi, C.R.; Fung, J.J.; Lu, L.; Qian, S. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology 2004, 40, 1312–1321. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.; Xu, M.J.; Cai, Y.; Wang, W.; Jiang, J.X.; Varga, Z.V.; Feng, D.; Pacher, P.; Kunos, G.; Torok, N.J.; et al. Neutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis. Cell. Mol. Gastroenterol. Hepatol. 2018, 5, 399–413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cai, X.; Li, Z.; Zhang, Q.; Qu, Y.; Xu, M.; Wan, X.; Lu, L. CXCL6-EGFR-induced Kupffer cells secrete TGF-β1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C-MYC/EZH2 pathway in liver fibrosis. J. Cell. Mol. Med. 2018, 22, 5050–5061. [Google Scholar] [CrossRef]
- Benedicto, A.; Herrero, A.; Romayor, I.; Marquez, J.; Smedsrød, B.; Olaso, B.; Arteta, B. Liver sinusoidal endothelial cell ICAM-1 mediated tumor/endothelial crosstalk drives the development of liver metastasis by initiating inflammatory and angiogenic responses. Sci. Rep. 2019, 9, 1–12. [Google Scholar] [CrossRef] [Green Version]
- Viñas, O.; Bataller, R.; Sancho-Bru, P.; Ginès, P.; Berenguer, C.; Enrich, C.; Ercilla, G.; Vives, J.; Gallart, T.; Arroyo, V.; et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 2003, 38, 919–929. [Google Scholar] [CrossRef] [PubMed]
- Alisi, A.; Romania, P.; Nobili, V.; Locatelli, F.; Fruci, D. Human hepatic stellate cells are liver-resident antigen-presenting cells. Hepatology 2011, 54, 1107. [Google Scholar] [CrossRef]
- Winau, F.; Hegasy, G.; Weiskirchen, R.; Weber, S.; Cassan, C.; Sieling, P.A.; Modlin, R.L.; Liblau, R.S.; Gressner, A.M.; Kaufmann, S.H.E. Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses. Immunity 2007, 26, 117–129. [Google Scholar] [CrossRef] [Green Version]
- Luk, J.M.; Zhang, Q.-S.; Lee, N.P.; Wo, J.Y.; Leung, P.P.; Liu, L.-X.; Hu, M.-Y.; Cheung, K.-F.; Hui, C.-K.; Lau, G.-K.; et al. Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. Liver Int. 2007, 27, 548–557. [Google Scholar] [CrossRef]
- Sato, Y.; Murase, K.; Kato, J.; Kobune, M.; Sato, T.; Kawano, I.; Takimoto, R.; Takada, K.; Miyanishi, K.; Matsunaga, T.; et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol. 2008, 26, 431–442. [Google Scholar] [CrossRef]
- Beljaars, L.; Weert, B.; Geerts, A.; Meijer, D.K.F.; Poelstra, K. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem. Pharmacol. 2003, 66, 1307–1317. [Google Scholar] [CrossRef]
- Beljaars, L.; Molema, G.; Schuppan, D.; Geerts, A.; De Bleser, P.J.; Weert, B.; Meijer, D.K.F.; Poelstra, K. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J. Biol. Chem. 2000, 275, 12743–12751. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adrian, J.E.; Kamps, J.A.A.M.; Poelstra, K.; Scherphof, G.L.; Meijer, D.K.F.; Kaneda, I. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes. J. Drug Target. 2007, 15, 75–82. [Google Scholar] [CrossRef]
- Hu, Q.; Lee, J.-Y.; Luo, Y. Nanoparticles Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis. Eng. Sci. 2019, 6, 12–21. [Google Scholar] [CrossRef]
- Michalopoulos, G.K.; Bhushan, B. Liver regeneration: Biological and pathological mechanisms and implications. Nat. Rev. Gastroenterol. Hepatol. 2020. [Google Scholar] [CrossRef] [PubMed]
- Kitade, M.; Kaji, K.; Yoshiji, H. Relationship between hepatic progenitor cell-mediated liver regeneration and non-parenchymal cells. Hepatol. Res. 2016, 46, 1187–1193. [Google Scholar] [CrossRef] [PubMed]
- Tummala, K.S.; Brandt, M.; Teijeiro, A.; Graña, O.; Schwabe, R.F.; Perna, C.; Djouder, N. Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells. Cell Rep. 2017, 19, 584–600. [Google Scholar] [CrossRef] [Green Version]
- Alqahtani, A.; Khan, Z.; Alloghbi, A.; Said Ahmed, T.S.; Ashraf, M.; Hammouda, D.M. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina 2019, 55, 526. [Google Scholar] [CrossRef] [Green Version]
- Yang, J.D.; Hainaut, P.; Gores, G.J.; Amadou, A.; Plymoth, A.; Roberts, L.R. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 589–604. [Google Scholar] [CrossRef]
- El-Serag, H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142, 1264–1273.e1261. [Google Scholar] [CrossRef] [Green Version]
- Younossi, Z.M.; Ratziu, V.; Loomba, R.; Rinella, M.; Anstee, Q.M.; Goodman, Z.; Bedossa, P.; Geier, A.; Beckebaum, S.; Newsome, P.N.; et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019, 394, 2184–2196. [Google Scholar] [CrossRef] [Green Version]
- Lazarus, J.V.; Colombo, M.; Cortez-Pinto, H.; Huang, T.T.; Miller, V.; Ninburg, M.; Schattenberg, J.M.; Seim, L.; Wong, V.W.S.; Zelber-Sagi, S. NAFLD–sounding the alarm on a silent epidemic. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 377–379. [Google Scholar] [CrossRef] [PubMed]
- Welzel, T.M.; Graubard, B.I.; Quraishi, S.; Zeuzem, S.; Davila, J.A.; El-Serag, H.B.; McGlynn, K.A. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 2013, 108, 1314–1321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mittal, S.; El-Serag, H.B.; Sada, Y.H.; Kanwal, F.; Duan, Z.; Temple, S.; May, S.B.; Kramer, J.R.; Richardson, P.A.; Davila, J.A. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2016, 14, 124–131.e121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, T.C.; Li, C.I.; Liu, C.S.; Lin, W.Y.; Lin, C.H.; Yang, S.Y.; Lin, C.C. Risk score system for the prediction of hepatocellular carcinoma in patients with type 2 diabetes: Taiwan Diabetes Study. Semin. Oncol. 2018, 45, 264–274. [Google Scholar] [CrossRef] [PubMed]
- Hirosumi, J.; Tuncman, G.; Chang, L.; Görgün, C.Z.; Uysal, K.T.; Maeda, K.; Karin, M.; Hotamisligil, G.S. A central role for JNK in obesity and insulin resistance. Nature 2002, 420, 333–336. [Google Scholar] [CrossRef]
- Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357, 539–545. [Google Scholar] [CrossRef]
- Lleo, A.; de Boer, Y.S.; Liberal, R.; Colombo, M. The risk of liver cancer in autoimmune liver diseases. Adv. Med. Oncol. 2019, 11, 1758835919861914. [Google Scholar] [CrossRef]
- Nowak, A.; Giger, R.S.; Krayenbuehl, P.A. Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study. Medicine 2018, 97, e12886. [Google Scholar] [CrossRef]
- Ramadori, P.; Cubero, F.J.; Liedtke, C.; Trautwein, C.; Nevzorova, Y.A. Alcohol and Hepatocellular Carcinoma: Adding Fuel to the Flame. Cancers 2017, 9, 130. [Google Scholar] [CrossRef] [Green Version]
- Gouas, D.; Shi, H.; Hainaut, P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy. Cancer Lett. 2009, 286, 29–37. [Google Scholar] [CrossRef] [PubMed]
- Golabi, P.; Fazel, S.; Otgonsuren, M.; Sayiner, M.; Locklear, C.T.; Younossi, Z.M. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine 2017, 96, e5904. [Google Scholar] [CrossRef] [PubMed]
- Berzigotti, A.; Reig, M.; Abraldes, J.G.; Bosch, J.; Bruix, J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. Hepatology 2015, 61, 526–536. [Google Scholar] [CrossRef] [PubMed]
- Teh, S.H.; Christein, J.; Donohue, J.; Que, F.; Kendrick, M.; Farnell, M.; Cha, S.; Kamath, P.; Kim, R.; Nagorney, D.M. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J. Gastrointest. Surg. 2005, 9, 1207–1215; discussion 1215. [Google Scholar] [CrossRef] [PubMed]
- Sapisochin, G.; Bruix, J. Liver transplantation for hepatocellular carcinoma: Outcomes and novel surgical approaches. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 203–217. [Google Scholar] [CrossRef] [PubMed]
- Xu, X.; Chen, J.; Wei, Q.; Liu, Z.-H.; Yang, Z.; Zhang, M.; Wang, G.-U.; Gao, J.; Yang, Z.; Guo, W.-E.; et al. EASL Clinical Practice Guidelines: Liver transplantation. J. Hepatol. 2016, 64, 433–485. [Google Scholar] [CrossRef]
- Shiina, S.; Sato, K.; Tateishi, R.; Shimizu, M.; Ohama, H.; Hatanaka, T.; Takawa, M.; Nagamatsu, H.; Imai, Y. Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can. J. Gastroenterol. Hepatol. 2018, 2018, 4756147. [Google Scholar] [CrossRef] [Green Version]
- Lencioni, R.; de Baere, T.; Soulen, M.C.; Rilling, W.S.; Geschwind, J.F. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 2016, 64, 106–116. [Google Scholar] [CrossRef] [Green Version]
- Keating, G.M. Sorafenib: A Review in Hepatocellular Carcinoma. Target. Oncol. 2017, 12, 243–253. [Google Scholar] [CrossRef]
- Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.-F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.-L.; Forner, A.; et al. Sorafenib in Advanced Hepatocellular Carcinoma. N. Engl. J. Med. 2008, 359, 378–390. [Google Scholar] [CrossRef]
- Al-Salama, Z.T.; Syed, Y.Y.; Scott, L.J. Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs 2019, 79, 665–674. [Google Scholar] [CrossRef] [PubMed]
- Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017, 389, 56–66. [Google Scholar] [CrossRef] [Green Version]
- Finkelmeier, F.; Waidmann, O.; Trojan, J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev. Anticancer 2018, 18, 1169–1175. [Google Scholar] [CrossRef] [PubMed]
- Zhu, A.X.; Finn, R.S.; Edeline, J.; Cattan, S.; Ogasawara, S.; Palmer, D.; Verslype, C.; Zagonel, V.; Fartoux, L.; Vogel, A.; et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 2018, 19, 940–952. [Google Scholar] [CrossRef]
- Zhu, A.X.; Kang, Y.K.; Yen, C.J.; Finn, R.S.; Galle, P.R.; Llovet, J.M.; Assenat, E.; Brandi, G.; Pracht, M.; Lim, H.Y.; et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019, 20, 282–296. [Google Scholar] [CrossRef]
- Sevic, I.; Spinelli, F.M.; Cantero, M.J.; Reszegi, A.; Kovalszky, I.; García, M.G.; Alaniz, L. The Role of the Tumor Microenvironment in the Development and Progression of Hepatocellular Carcinoma. In Hepatocellular Carcinoma; Tirnitz-Parker, J.E.E., Ed.; Codon Publications: Brisbane, QLD, Australia, 2019. [Google Scholar] [CrossRef] [Green Version]
- Tanaka, Y.; Tateishi, R.; Koike, K. Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2018, 19, 3070. [Google Scholar] [CrossRef] [Green Version]
- Ritz, T.; Krenkel, O.; Tacke, F. Dynamic plasticity of macrophage functions in diseased liver. Cell. Immunol. 2018, 330, 175–182. [Google Scholar] [CrossRef]
- Higashi, T.; Friedman, S.L.; Hoshida, Y. Hepatic stellate cells as key target in liver fibrosis. Adv. Drug Deliv. Rev. 2017, 121, 27–42. [Google Scholar] [CrossRef]
- Mattyasovszky, S.G.; Wollstädter, J.; Martin, A.; Ritz, U.; Baranowski, A.; Ossendorf, C.; Rommens, P.M.; Hofmann, A. Inhibition of Contractile Function in Human Joint Capsule Myofibroblasts by Targeting the TGF-β1 and PDGF Pathways. PLoS ONE 2016, 11, e0145948. [Google Scholar] [CrossRef] [Green Version]
- Degroote, H.; Van Dierendonck, A.; Geerts, A.; Van Vlierberghe, H.; Devisscher, L. Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma. J. Immunol. Res. 2018, 2018, 7819520. [Google Scholar] [CrossRef] [Green Version]
- Yeung, O.W.; Lo, C.M.; Ling, C.C.; Qi, X.; Geng, W.; Li, C.X.; Ng, K.T.; Forbes, S.J.; Guan, X.Y.; Poon, R.T.; et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J. Hepatol. 2015, 62, 607–616. [Google Scholar] [CrossRef] [PubMed]
- Kuang, D.M.; Zhao, Q.; Peng, C.; Xu, J.; Zhang, J.P.; Wu, C.; Zheng, L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 2009, 206, 1327–1337. [Google Scholar] [CrossRef] [PubMed]
- Wu, K.; Kryczek, I.; Chen, L.; Zou, W.; Welling, T.H. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res. 2009, 69, 8067–8075. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mueller, L.; Goumas, F.A.; Affeldt, M.; Sandtner, S.; Gehling, U.M.; Brilloff, S.; Walter, J.; Karnatz, N.; Lamszus, K.; Rogiers, X.; et al. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am. J. Pathol. 2007, 171, 1608–1618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cirri, P.; Chiarugi, P. Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012, 31, 195–208. [Google Scholar] [CrossRef] [PubMed]
- Ramachandran, P.; Pellicoro, A.; Vernon, M.A.; Boulter, L.; Aucott, R.L.; Ali, A.; Hartland, S.N.; Snowdon, V.K.; Cappon, A.; Gordon-Walker, T.T.; et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl. Acad. Sci. USA 2012, 109, E3186–E3195. [Google Scholar] [CrossRef] [Green Version]
- Baeck, C.; Wei, X.; Bartneck, M.; Fech, V.; Heymann, F.; Gassler, N.; Hittatiya, K.; Eulberg, D.; Luedde, T.; Trautwein, C.; et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology 2014, 59, 1060–1072. [Google Scholar] [CrossRef]
- Chen, Y.; Zhang, S.; Wang, Q.; Zhang, X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J. Hematol. Oncol. 2017, 10, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Das, R.P.; Gandhi, V.V.; Singh, B.G.; Kunwar, A. Passive and Active Drug Targeting: Role of Nanocarriers in Rational Design of Anticancer Formulations. Curr. Pharm. Des. 2019, 25, 3034–3056. [Google Scholar] [CrossRef]
- Kaps, L.; Nuhn, L.; Aslam, M.; Brose, A.; Foerster, F.; Rosigkeit, S.; Renz, P.; Heck, R.; Kim, Y.O.; Lieberwirth, I.; et al. In Vivo Gene-Silencing in Fibrotic Liver by siRNA-Loaded Cationic Nanohydrogel Particles. Adv. Healthc. Mater. 2015, 4, 2809–2815. [Google Scholar] [CrossRef]
- Leber, N.; Kaps, L.; Yang, A.; Aslam, M.; Giardino, M.; Klefenz, A.; Choteschovsky, N.; Rosigkeit, S.; Mostafa, A.; Nuhn, L.; et al. α-Mannosyl-Functionalized Cationic Nanohydrogel Particles for Targeted Gene Knockdown in Immunosuppressive Macrophages. Macromol. Biosci. 2019, 19, e1900162. [Google Scholar] [CrossRef] [PubMed]
- Scodeller, P.; Simón-Gracia, L.; Kopanchuk, S.; Tobi, A.; Kilk, K.; Säälik, P.; Kurm, K.; Squadrito, M.L.; Kotamraju, V.R.; Rinken, A.; et al. Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide. Sci. Rep. 2017, 7, 14655. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lopez-Pelaez, M.; Lamont, D.J.; Peggie, M.; Shpiro, N.; Gray, N.S.; Cohen, P. Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells. Proc. Natl. Acad. Sci. USA 2014, 111, 17432–17437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, F.; Parayath, N.N.; Ene, C.I.; Stephan, S.B.; Koehne, A.L.; Coon, M.E.; Holland, E.C.; Stephan, M.T. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 2019, 10, 3974. [Google Scholar] [CrossRef] [PubMed]
- Bobbin, M.L.; Rossi, J.J. RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? Annu. Rev. Pharm. Toxicol. 2016, 56, 103–122. [Google Scholar] [CrossRef] [PubMed]
- Zins, K.; Abraham, D. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing. Methods Mol. Biol. 2020, 2115, 289–325. [Google Scholar] [CrossRef]
- Shobaki, N.; Sato, Y.; Suzuki, Y.; Okabe, N.; Harashima, H. Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. J. Control. Release 2020, 325, 235–248. [Google Scholar] [CrossRef]
- McNelis, J.C.; Olefsky, J.M. Macrophages, immunity, and metabolic disease. Immunity 2014, 41, 36–48. [Google Scholar] [CrossRef] [Green Version]
- Loomba, R.; Lawitz, E.; Mantry, P.S.; Jayakumar, S.; Caldwell, S.H.; Arnold, H.; Diehl, A.M.; Djedjos, C.S.; Han, L.; Myers, R.P.; et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology 2018, 67, 549–559. [Google Scholar] [CrossRef]
- Tu, K.N.; Lie, J.D.; Wan, C.K.V.; Cameron, M.; Austel, A.G.; Nguyen, J.K.; Van, K.; Hyun, D. Osteoporosis: A Review of Treatment Options. Pharm. Ther. 2018, 43, 92–104. [Google Scholar]
- Menshawy, A.; Mattar, O.; Abdulkarim, A.; Kasem, S.; Nasreldin, N.; Menshawy, E.; Mohammed, S.; Abdel-Maboud, M.; Gadelkarim, M.; El Ashal, G.G.; et al. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: Systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2018, 26, 1029–1038. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Acker, H.H.; Anguille, S.; Willemen, Y.; Smits, E.L.; Van Tendeloo, V.F. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. Pharmathera 2016, 158, 24–40. [Google Scholar] [CrossRef] [PubMed]
- Yu, X.; Chen, L.; Liu, J.; Dai, B.; Xu, G.; Shen, G.; Luo, Q.; Zhang, Z. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nat. Commun. 2019, 10, 574. [Google Scholar] [CrossRef] [PubMed]
- Tang, T.; Sui, Y.; Lian, M.; Li, Z.; Hua, J. Pro-inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-induced cell death. PLoS ONE 2013, 8, e81949. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Li, N.; Yang, L.; Xie, H.; Yang, Y.; Wang, H.; Wu, C.; Shen, T.; Zhu, Q. Bradykinin contributes to immune liver injury via B2R receptor-mediated pathways in trichloroethylene sensitized mice: A role in Kupffer cell activation. Toxicology 2019, 415, 37–48. [Google Scholar] [CrossRef]
- Bros, M.; Nuhn, L.; Simon, J.; Moll, L.; Mailander, V.; Landfester, K.; Grabbe, S. The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery. Front. Immunol. 2018, 9, 1760. [Google Scholar] [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cacicedo, M.L.; Medina-Montano, C.; Kaps, L.; Kappel, C.; Gehring, S.; Bros, M. Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells 2020, 9, 1985. https://doi.org/10.3390/cells9091985
Cacicedo ML, Medina-Montano C, Kaps L, Kappel C, Gehring S, Bros M. Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells. 2020; 9(9):1985. https://doi.org/10.3390/cells9091985
Chicago/Turabian StyleCacicedo, Maximiliano L., Carolina Medina-Montano, Leonard Kaps, Cinja Kappel, Stephan Gehring, and Matthias Bros. 2020. "Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy" Cells 9, no. 9: 1985. https://doi.org/10.3390/cells9091985